sovaldi
US court upholds verdict voiding MSD’s claim to $200m from Gilead in patent dispute
April 26, 2018Sales and Marketing Gilead, MSD, Merck, harvoni, hepatitis C, pharma, sovaldi
MSD has taken a legal hit after a US appeals court upheld a ruling that the pharma giant had illicitly …
New hepatitis C combo boasts 97% cure rate for just $300
April 12, 2018Research and Development AbbVie, DNDi, Drugs for Neglected Diseases initiative, Gilead, HCV, Pharco Pharmaceuticals, hepatitis C, pharma, sovaldi
A partnership of the not-for-profit organisation Drugs for Neglected Diseases initiative (DNDi) and Egyptian drug firm Pharco Pharmaceuticals is working …
Long-running, $2.5bn lawsuit swings in Gilead’s favour
February 19, 2018Sales and Marketing Gilead, MSD, biotech, drugs, harvoni, pharma, pharmaceutical, sovaldi
The fate of pharma company’s profits and losses largely rests on product approvals and the sales team behind them but, …
Gilead launches hep C drug Sovaldi in China at one-fifth of US price
November 29, 2017Research and Development, Sales and Marketing China, Gilead, hepatitis C, pharma, sovaldi
Gilead has officially launched its hepatitis C drug Sovaldi (sofosbuvir) in the Chinese market, but with one major caveat: it …
FDA approves first two antiviral hep C drugs for paediatric patients
April 10, 2017Sales and Marketing FDA, harvoni, hepatitis C, sovaldi
The FDA has given the go-ahead for two hepatitis C treatments for use in young and adolescent patients: Sovaldi (sofosbuvir) …
Judge reverses verdict in MSD/Gilead hepatitis C dispute
June 7, 2016Manufacturing and Production, Research and Development, Sales and Marketing Gilead, MSD, Merck, dispute, patent, reversal, sovaldi
A US district judge has reversed a previous court decision which favoured MSD, called Merck in the US, over Gilead …
Gilead’s Sovaldi gets Indian patent; critics call it “major blow” to patient access
May 11, 2016Manufacturing and Production, Research and Development, Sales and Marketing India, harm, hepatitis, patent, patient access, sovaldi
Gilead has been granted a patent for its hepatitis C drug, Sovaldi (sofosbuvir), in India which has sparked dismay among …
Federal jury rules in MSD’s favour in Gilead blockbuster hepatitis C drug dispute
March 23, 2016Medical Communications, Research and Development Gilead, MSD, blockbuster, federal court, federal jury, hit, patents, sales, sales hit, sofosbuvir, sovaldi
Gilead’s dominance of the hepatitis C market is under severe threat after a federal jury ruled in favour of MSD …
Gilead’s Sovaldi wins Drug Discovery of the Year Award
December 16, 2015Research and Development British Pharmacological Society, Gilead, Gilead Sciences, hepatitis C, sofosbuvir, sovaldi
Gilead Science’s hepatitis C treatment Sovaldi has been awarded the British Pharmacological Society’s prestigious Drug Discovery of the Year 2016. …
Gilead awaits EU decision on hep C combo treatment
December 8, 2015Research and Development EMA, Gilead, SOF/VEL, accelerated assessment, hepatitis C, sovaldi, velpatasvir
The EMA has granted Gilead Sciences an accelerated assessment for its application for a new Sovaldi combination treatment.The combination contains …
FDA sued over failure to disclose Sovaldi data
June 30, 2015Sales and Marketing FDA, Gilead, hepatitis C, sofosbuvir, sovaldi
Two groups that campaign for wider access to medicines have filed a lawsuit against the FDA, in a bid to …
China rejects Gilead’s Sovaldi patent
June 24, 2015Research and Development, Sales and Marketing China, Gilead, hep C, sofosbuvir, sovaldi
Manufacturer of the blockbuster hepatitis C treatment Sovaldi Gilead has seen its application for a patent in China rejected following …
The Pharmafocus debate: Is the price of new hepatitis C treatments fair?
April 27, 2015Research and Development, Sales and Marketing Doctors of the World, Drug pricing, EFPIA, Gilead, MSF, drug cost, hepatitis C, patents, sofosbuvir, sovaldi
YES – says Richard Bergström, director general of the European Federation of Pharmaceutical Industries and Associations (EFPIA), who argues that …
Gilead presents new Sovaldi data
April 23, 2015Sales and Marketing GS-5816, GS-9857, Gilead, NS3/4A, SVR12, hepatitis C, sofosbuvir, sovaldi
Gilead is looking to several new studies to support future new Sovaldi combinations and broadened treatment groups for its hepatitis …
BMS resubmits hepatitis C drug
March 13, 2015Sales and Marketing BMS, NDA, daclatasvir gilead, hepatitis C, sovaldi
Bristol-Myers Squibb has resubmitted its hepatitis C (HCV) treatment for FDA approval despite previously backing out, as it spots a …
